Top ▲


Click here for help

Immunopharmacology Ligand target has curated data in GtoImmuPdb

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 244 3q13.31 TIGIT T cell immunoreceptor with Ig and ITIM domains 3
Mouse 1 249 16 B4 Tigit T cell immunoreceptor with Ig and ITIM domains
Rat - - 11q21 Tigit T cell immunoreceptor with Ig and ITIM domains
Previous and Unofficial Names Click here for help
T-cell immunoreceptor with Ig and ITIM domains | V-set and immunoglobulin domain containing 9 | V-set and transmembrane domain containing 3 | VSIG9 | VSTM3 | WUCAM [1]
Database Links Click here for help
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
RefSeq Nucleotide
RefSeq Protein
Immunopharmacology Comments
TIGIT is now considered as an alternate inhibitory immune checkpoint protein which may have potential immunotherapeutic potential, particularly in conditions refractory to more established PD-1 checkpoint inhibition. Given its presence on T cells and NK cells, TIGIT offers an intervention point for targeting both the adaptive and innate arms of the immune system. Clinical development of anti-TIGIT monoclonal antibodies is in preliminary stages. Combination therapies with existing immune checkpoint inhibitors are considered particularly promising. MTIG7192A (NCT02794571; ± anti-PD-L1 atezolizumab) and BMS-986207 (NCT02913313; ± anti-PD-1 nivolumab) are two early phase potential immuno-oncology mAbs that prevent TIGIT-PVR interaction. OncoMed and Merck also have anti-TIGIT antibodies in their immuno-oncology pipelines (OMP-313M32/etigilimab and MK-7684 respectively).
Cell Type Associations
Immuno Cell Type:  Innate lymphoid cells
Cell Ontology Term:   group 1 innate lymphoid cell (CL:0001067)
group 3 innate lymphoid cell (CL:0001071)
Comment:  TIGIT is expressed by human ILC1s and ILC3s.
References:  2
Immuno Cell Type:  Natural killer cells
References:  2-3
Immuno Cell Type:  T cells
Comment:  Expressed on regulatory, memory and activated T cells.
References:  3
Immuno Process Associations
Immuno Process:  T cell (activation)
Immuno Process:  Immune regulation
Immuno Process:  Cytokine production & signalling
Immuno Process:  Chemotaxis & migration
Immuno Process:  Cellular signalling
General Comments
TIGIT was originally identified as a high affinity binding partner of the poliovirus receptor (PVR; P15151). TIGIT-PVR interaction promotes the generation of mature immunoregulatory dendritic cells and leads to suppression of T cell activation.
The TIGIT protein contains an immunoglobulin (Ig)-like domain that resembles the antibody variable domain, that has been coined the 'V-set domain'. The genes for all human V-set domain containing proteins are listed in HGNC gene group 590.


Show »

1. Boles KS, Vermi W, Facchetti F, Fuchs A, Wilson TJ, Diacovo TG, Cella M, Colonna M. (2009) A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC. Eur J Immunol, 39 (3): 695-703. [PMID:19197944]

2. Mariotti FR, Quatrini L, Munari E, Vacca P, Moretta L. (2019) Innate Lymphoid Cells: Expression of PD-1 and Other Checkpoints in Normal and Pathological Conditions. Front Immunol, 10: 910. [PMID:31105707]

3. Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, Tom I, Ivelja S, Refino CJ, Clark H et al.. (2009) The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol, 10 (1): 48-57. [PMID:19011627]

How to cite this page

Immunoglobulin like domain containing proteins: TIGIT. Last modified on 26/02/2024. Accessed on 14/06/2024. IUPHAR/BPS Guide to PHARMACOLOGY,